New growth under the Fifth Five-Year Medium-Term Management Plan

「Under the Fifth Five-Year Medium-Term Management Plan, which began with the 152nd fiscal year, the growth of domestic sales of new products developed in-house, including Uptravi, a treatment for pulmonary arterial hypertension, Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, and Vidaza, a treatment for myelodysplastic syndromes, together with royalty income from overseas sales of Uptravi and co-promotion income from Opsumit, a treatment for pulmonary arterial hypertension, contributed to the achievement of net sales of ¥110 billion, operating income of ¥18 billion and ROE of 10%. As shown by the substantial increase in market capitalization, one indicator of corporate value, the Company was able to enhance its meaningful role in society.」

「In the fiscal year ending March 2019, the final year of the Fifth Medium-Term Management Plan, we aim for net sales of ¥110 billion, operating income of ¥18 billion, net income attributable to owners of the parent of ¥12 billion, EPS of ¥180 and ROE of 10%.」

「Under the Fifth Five-Year Medium-Term Management Plan, which began in the fiscal year ended March 2015, we aim to achieve new growth based on the foundation established under the Fourth Medium-Term Management Plan.」